Literature DB >> 12226006

From anti-inflammatory drugs through antifibrotic agents to lung transplantation: a long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis.

Moisés Selman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12226006     DOI： 10.1378/chest.122.3.759

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  7 in total

1.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis.

Authors:  Marco Chilosi; Venerino Poletti; Alberto Zamò; Maurizio Lestani; Licia Montagna; Paola Piccoli; Serena Pedron; Manuela Bertaso; Aldo Scarpa; Bruno Murer; Alessandra Cancellieri; Roberta Maestro; Gianpietro Semenzato; Claudio Doglioni
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

2.  Inflammatory cells as a source of airspace extracellular superoxide dismutase after pulmonary injury.

Authors:  Roderick J Tan; Janet S Lee; Michelle L Manni; Cheryl L Fattman; Jacob M Tobolewski; Mingquan Zheng; Jay K Kolls; Thomas R Martin; Tim D Oury
Journal:  Am J Respir Cell Mol Biol       Date:  2005-10-13       Impact factor: 6.914

3.  High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation.

Authors:  Michael Rehman; Simone Vodret; Luca Braga; Corrado Guarnaccia; Fulvio Celsi; Giulia Rossetti; Valentina Martinelli; Tiziana Battini; Carlin Long; Kristina Vukusic; Tea Kocijan; Chiara Collesi; Nadja Ring; Natasa Skoko; Mauro Giacca; Giannino Del Sal; Marco Confalonieri; Marcello Raspa; Alessandro Marcello; Michael P Myers; Sergio Crovella; Paolo Carloni; Serena Zacchigna
Journal:  JCI Insight       Date:  2019-04-18

4.  Small interfering RNAs (siRNAs) targeting TGF-beta1 mRNA suppress asbestos-induced expression of TGF-beta1 and CTGF in fibroblasts.

Authors:  Tai-Cheng Lai; Derek A Pociask; MaryBeth Ferris; Hong T Nguyen; Charles A Miller; Arnold Brody; Deborah Sullivan
Journal:  J Environ Pathol Toxicol Oncol       Date:  2009       Impact factor: 3.567

Review 5.  New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy.

Authors:  Mehrnaz Gharaee-Kermani; Margaret R Gyetko; Biao Hu; Sem H Phan
Journal:  Pharm Res       Date:  2007-03-01       Impact factor: 4.580

6.  Wet-dry-wet drug screen leads to the synthesis of TS1, a novel compound reversing lung fibrosis through inhibition of myofibroblast differentiation.

Authors:  Nadja Anneliese Ruth Ring; Maria Concetta Volpe; Tomaž Stepišnik; Maria Grazia Mamolo; Panče Panov; Dragi Kocev; Simone Vodret; Sara Fortuna; Antonella Calabretti; Michael Rehman; Andrea Colliva; Pietro Marchesan; Luca Camparini; Thomas Marcuzzo; Rossana Bussani; Sara Scarabellotto; Marco Confalonieri; Tho X Pham; Giovanni Ligresti; Nunzia Caporarello; Francesco S Loffredo; Daniele Zampieri; Sašo Džeroski; Serena Zacchigna
Journal:  Cell Death Dis       Date:  2021-12-17       Impact factor: 8.469

7.  An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling in ex vivo human precision-cut lung slices.

Authors:  Muzamil Majid Khan; Daniel Poeckel; Aliaksandr Halavatyi; Joanna Zukowska-Kasprzyk; Frank Stein; Johanna Vappiani; Daniel C Sevin; Christian Tischer; Nico Zinn; Jessica D Eley; Natasja Stæhr Gudmann; Thomas Muley; Hauke Winter; Andrew J Fisher; Carmel B Nanthakumar; Giovanna Bergamini; Rainer Pepperkok
Journal:  Eur Respir J       Date:  2021-07-01       Impact factor: 16.671
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.